Long-acting bronchodilator therapy should be considered when a COPD patient is symptomatic. For patients whose conditions are not sufficiently controlled by monotherapy, combining medications of different classes seems a convenient treatment for obtaining better results. The current opinion is that it is advantageous to develop inhalers containing several classes of long-acting bronchodilator drugs in an attempt to simplify treatment regimes as much as possible and to serve as a basis for improved 'triple therapy' combinations through co-formulation with novel anti-inflammatory compounds, such as inhaled PDE4 inhibitors, that could deliver three complementary therapeutic effects. © 2006 Elsevier Ltd. All rights reserved.

Cazzola M., M.M. (2006). The effective treatment of COPD: Anticholinergics and what else?. DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES, 3(3), 277-286 [10.1016/j.ddstr.2006.09.009].

The effective treatment of COPD: Anticholinergics and what else?

CAZZOLA, MARIO;
2006

Abstract

Long-acting bronchodilator therapy should be considered when a COPD patient is symptomatic. For patients whose conditions are not sufficiently controlled by monotherapy, combining medications of different classes seems a convenient treatment for obtaining better results. The current opinion is that it is advantageous to develop inhalers containing several classes of long-acting bronchodilator drugs in an attempt to simplify treatment regimes as much as possible and to serve as a basis for improved 'triple therapy' combinations through co-formulation with novel anti-inflammatory compounds, such as inhaled PDE4 inhibitors, that could deliver three complementary therapeutic effects. © 2006 Elsevier Ltd. All rights reserved.
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/10 - Malattie dell'Apparato Respiratorio
English
Con Impact Factor ISI
acetylcysteine; antiinflammatory agent; antioxidant; arformoterol; beta 2 adrenergic receptor stimulating agent; bronchodilating agent; budesonide; carmoterol; cholinergic receptor blocking agent; corticosteroid; fluticasone propionate; fluticasone propionate plus salmeterol; formoterol; gsk 159797; gsk 159802; gsk 233705; gsk 597901; gsk 678007; gsk 685698; gw 642444; indacaterol; muscarinic receptor blocking agent; nitric oxide synthase inhibitor; nva 237; phosphodiesterase IV inhibitor; salbutamol; salmeterol; theophylline; tiotropium bromide; unclassified drug; unindexed drug; asthma; bronchodilatation; chronic obstructive lung disease; clinical trial; combination chemotherapy; disease exacerbation; drug efficacy; drug formulation; drug potentiation; forced expiratory volume; human; inhaler; lung function; monotherapy; quality of life; respiratory tract disease; review; symptom; treatment outcome
Cazzola M., M.M. (2006). The effective treatment of COPD: Anticholinergics and what else?. DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES, 3(3), 277-286 [10.1016/j.ddstr.2006.09.009].
Cazzola, M; Matera, Mg
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/40928
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact